Search results
IGM Biosciences announces refocusing of Sanofi collaboration (NASDAQ:IGMS)
Seeking Alpha· 1 week agoIGM Biosciences and Sanofi are refocusing their collaboration agreement on immunology/inflammation ...
Sanofi shrinks IGM antibody partnership amid pipeline reprioritization
FierceBiotech· 1 week agoSanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three IgM agonist antibodies for immunology
Sanofi crosses Sjögren’s off $5B drug’s hit list after phase 2 data disappoint
FierceBiotech· 2 days agoSanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product”...
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Seeking Alpha· 1 day agoSanofi (NASDAQ:NASDAQ:SNY) Q1 2024 Earnings Conference Call April 25, 2024 8:30 AM ETCompany ParticipantsPaul Hudson - Chief Executive...
Sanofi to overhaul US operations of vaccines, cut jobs
AOL· 1 week agoSanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on ...
Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $55.00
ETF DAILY NEWS· 1 week agoShares of Sanofi (NASDAQ:SNY – Get Free Report) have earned a consensus recommendation of “Hold” from...MarketBeat.com reports. One investment analyst has rated the stock ...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Morningstar· 2 days agoSanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) ...
Q2 2024 EPS Estimates for Sanofi (NASDAQ:SNY) Cut by Leerink Partnrs
ETF DAILY NEWS· 6 days agoSanofi (NASDAQ:SNY – Free Report) – Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Sanofi in a research report issued to clients ...
Sanofi pulls off phase 3 LUNA landing, sparking race to regulators for BTK inhibitor
FierceBiotech· 4 days agoThe candidate, rilzabrutinib, is an oral, reversible BTK inhibitor that was already in phase 3 when Sanofi bought Principia. Researchers designed the candidate to have a lower ...
Sanofi profit slips on generic competition and currency effects
Reuters via Yahoo Finance· 2 days ago(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap...